CSL Limited provided earnings guidance for the first half Ended 31 December 2016 and Fiscal Year 2017. The company expects to report NPAT of approximately USD 800 million for the six months ended 31 December 2016. The Group NPAT for fiscal year 2017 was expected to grow approximately 11% at constant currency on the fiscal year 2016 result, after adjusting for the one-off gains and costs associated with the acquisition of the Novartis influenza vaccines business. Combining this expected first half fiscal 2017 profit with anticipated performance for the second half of fiscal 2017, the company now expects to deliver NPAT growth for fiscal year 2017 in the range of approximately 18% to 20% at constant currency on the fiscal year 2016 result, after adjusting for the one-off gains and costs associated with the acquisition of the Novartis influenza vaccines business.